PatternsRadar
Sign in

AARTIPHARMAarti Pharmalabs Limited

NSE
Full chart
975.00INR+28.40 (+3.00%)Close · 6 Oct 2026
7 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹8,841 CrMarket cap
41.5P/E (TTM)
48.1%Delivery

Filings & corporate actions

14 results filed
CSV
Next results · Q2 FY27
Expected 29 Oct 2026 – 9 Nov 2026
Estimate: filed 29–40 days after quarter end, last 3 times
Dividend
₹2.00 per share · last 15 Sept 2026
2026
  • 15 SeptdividendDividend · ₹2.00 per share-4.5%
  • 7 AugresultsResults · Q1 FY27 · consolidated and standalone+20.0%NSE
  • 16 JulshareholdingShareholding · 30 Jun 2026-0.1%NSE
  • 25 MayresultsResults · Q4 FY26 · consolidated and standalone-5.2%NSE
  • 16 AprshareholdingShareholding · 31 Mar 2026-0.4%NSE
  • 16 FebdividendDividend · ₹1.50 per share+0.2%
  • 9 FebresultsResults · Q3 FY26 · consolidated and standalone-3.8%NSE
  • 16 JanshareholdingShareholding · 31 Dec 2025+1.4%NSE

Reaction to results · all yearsrose on day 0 in 3 of 14 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY277 Aug 2026+20.0%+25.7%+25.8%22.2×
Q4 FY2625 May 2026-5.2%-15.1%-3.1%2.4×
Q3 FY269 Feb 2026-3.8%-8.9%-14.3%2.6×
Q2 FY269 Nov 2025-11.4%-15.7%-19.4%9.7×
Q1 FY2612 Aug 2025-7.7%+0.2%+8.2%5.1×
Q4 FY2510 May 2025+4.4%+11.7%+19.0%4.5×
Q3 FY256 Feb 2025+6.9%+15.7%+16.1%24.0×
Q2 FY2529 Oct 2024-3.7%+4.5%-1.3%2.1×
Q1 FY255 Aug 2024-3.0%-8.4%+10.5%0.9×
Q4 FY2414 May 2024-5.0%-1.5%-1.9%2.4×
Q3 FY247 Feb 2024-6.9%-6.7%-18.3%1.9×
Q2 FY248 Nov 2023-6.2%-5.8%+13.6%2.4×
Q1 FY245 Aug 2023-3.4%-2.0%+23.0%1.5×
Q4 FY2313 May 2023-6.8%-16.6%-5.3%2.1×
Average-2.3%-1.6%+3.8%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+38.7%
Profit YoY+53.8%
Interest cost YoY+83.6%
Revenue QoQ-8.0%
Profit QoQ+24.6%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+0.5%—————
Profit-2.7%—————

Key data

CSV
Open954.00
Day range954.00 – 987.00
52-week range585.00 – 1,002.40
From 52w high-2.7%
RSI (14)65.7
ATR (14)46.10
Volume5.37L
Avg volume (20D)8.79L
Rel volume0.61×
Volatility (1Y)44.8%
Turnover₹52.4Cr
SMA 50 / 200831.17 / 737.46

Delivery percentage

Latest · 6 Oct 202648.1%
20-day avg42.5%
1-year avg47.5%
Percentile (own history)41st
Range9.7–100.0%
Sessions913

Over the last 20 sessions AARTIPHARM settled 42.5% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 47.5%, so recent sessions are running 5.0 points lower than usual. The latest session ranks higher than 41% of the 913 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+3.00%+6.67%+12.31%+39.39%+51.01%+18.32%

Valuation

CSV
Market cap₹8,841 Cr
P/E (TTM)41.5
EPS (TTM)23.51
Shares outstanding9.07Cr
Listed30 Jan 2023

Ownership

CSV
Promoter42.86%
Promoter Δ QoQ-0.22 pp
Public57.14%
FII8.17%
DII7.22%
Pledged11.08%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)418.3432.3582.6535.8
YoY chg-8.7%-19.6%+3.3%+38.7%
Net profit (₹ Cr)27.948.061.176.1
YoY chg-48.9%-35.2%-30.8%+53.8%
Net margin6.7%11.1%10.5%14.2%
EPS3.085.296.748.39

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 42.86% · public 57.14%
13 Jan 2023: promoter 44.16%31 Mar 2023: promoter 45.98%30 Jun 2023: promoter 45.98%30 Sept 2023: promoter 46.30%31 Dec 2023: promoter 46.46%31 Mar 2024: promoter 46.46%30 Jun 2024: promoter 46.46%30 Sept 2024: promoter 46.10%31 Dec 2024: promoter 44.66%31 Mar 2025: promoter 44.29%30 Jun 2025: promoter 43.72%30 Sept 2025: promoter 42.88%31 Dec 2025: promoter 43.10%31 Mar 2026: promoter 43.08%30 Jun 2026: promoter 42.86%
2023-012026-06
  • Promoter
  • Public and others
Promoter
42.86%
Public
57.14%
Promoter change
-0.22 pp
Filed
16 Jul 2026
FII
8.17%
DII
7.22%
Promoter pledged
11.08%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24AQ3 FY24AQ4 FY24AQ1 FY25AQ2 FY25AQ3 FY25AQ4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations439.8448.7505.8555.5458.0537.8563.8386.2418.3432.3582.6535.8
Other income1.01.42.02.24.55.0(1.6)1.60.1(0.4)8.10.5
Total income440.8450.1507.8557.7462.5542.8562.2387.8418.4431.9590.7536.2
Total expenses373.8376.3412.0484.0390.7442.2447.5320.5379.1371.2514.5442.6
└ Finance costs3.94.54.74.85.510.06.66.810.712.616.912.9
└ Depreciation18.118.819.120.220.923.022.822.824.828.628.230.0
Profit before tax67.073.895.873.771.8100.6114.667.339.357.976.293.7
Tax expense15.221.130.518.217.126.626.316.010.814.920.624.9
Net profit51.852.865.355.554.674.088.349.527.948.061.176.1
EPS5.725.827.206.126.038.169.755.463.085.296.748.40
Net margin11.78%11.76%12.90%9.98%11.93%13.76%15.67%12.82%6.67%11.09%10.49%14.21%
PBT margin15.22%16.45%18.93%13.26%15.67%18.71%20.33%17.41%9.40%13.40%13.07%17.48%
Tax rate22.63%28.52%31.85%24.73%23.89%26.47%22.93%23.72%27.38%25.74%26.99%26.61%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 7 Aug 2026.

AARTIPHARM at a glance

  • AARTIPHARM closed at ₹975 on 6 Oct 2026, +3.00% on the day, +18.3% over one year, 2.7% below its 52-week high of ₹1,002.4.
  • Delivery was 48.1% of traded quantity on 6 Oct 2026, the 41st percentile of its own 913 sessions with a reading (20-session average 42.5%, 1-year average 47.5%).
  • Market capitalisation is ₹8,841 crore at a trailing P/E of 41.5 (trailing EPS ₹23.51).
  • Q1 FY27 results (consolidated, filed 7 Aug 2026): revenue ₹536 crore (+38.7% year on year), net profit ₹76 crore (+53.8%); the price moved +20.0% on the first session after.
  • Promoters held 42.86% at 30 Jun 2026, down 0.22 percentage points on the previous filing, with 11.08% of promoter shares pledged.
  • Q2 FY27 results are expected between 29 Oct 2026 and 9 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE0LRU01027
SeriesEQ
Listed30 Jan 2023
History from30 Jan 2023
Sessions913
Turnover rank#367

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE